ПРИМЕНЕНИЕ ЭРИБУЛИНА И ИНГИБИТОРОВ mTOR В КАЧЕСТВЕ КОМБИНИРОВАННОЙ ТЕРАПИИ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ

• 收藏
• 分享

专利权人:

发明人:

申请号：

RU2016136504

公开号：

RU2016136504A3

申请日:

申请国别(地区):

RU

年份:

2018

代理人:

摘要：

There is provided thus wherein by with one or more mammalian target of rapamycin (mTOR) inhibitor (such as everolimus, ridaforolimus, and temsirolimu) combination management eribulin (such as eribulin mesylate, that is E7389, Halaven) for treating cancer (such as breast cancer, lung cancer, cancer of pancreas, primitive neuroectodermal tumors, lung cancer, oophoroma, carcinoma of endometrium, pharynx cancer, the cancer of the esophagus in a main body (such as a human patient) in needs, and sarcoma) method and external member.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/